14Jul 2022
Impact of a Population Genomic Screening Program on Health Behaviors Related to Familial Hypercholesterolemia Risk Reduction

Impact of a Population Genomic Screening Program on Health Behaviors Related to Familial Hypercholesterolemia Risk Reduction

Limited information is available regarding clinician and participant behaviours after disclosure of genomic risk variants for familial hypercholesterolemia (FH) from a population genomic screening program. Most (90%) had a hypercholesterolemia diagnosis but no specific FH diagnosis before the disclosure; 29% had an FH diagnosis post-disclosure. After exposure, clinicians made 36 prescription changes in 38% of participants, mostly in participants who did not achieve pre-disclosure LDL goals (81%). Despite disclosing an FH risk variant, non-prescribing and nonadherence to lipid-lowering therapy remained high. However, lipid levels decreased when clinicians intensified medication regimens and participants adhered to medications.

  • #cardiology

Like

Save

Share